BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2018 Results - Earnings Call Transcript [Seeking Alpha]
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
BioXcel Therapeutics, Inc. (NASDAQ: BTAI ) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Lee Roth - SVP, The Ruth Group Vimal Mehta - Founder, CEO, President, Secretary & Director Richard Steinhart - CFO Frank Yocca - Chief Scientific Officer Vincent O'Neill - SVP & Chief Medical Officer Analysts Jason Zemansky - Barclays Bank Sumant Kulkarni - Canaccord Genuity Limited Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, everyone, and welcome to the BioXcel Therapeutics Second Quarter 2018 Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Lee Roth. Please go ahead. Lee Roth Thanks, Anne. Good afternoon, and once again, thank you all for joining us for BioXcel Therapeutics Second Quarter 2018 Earnings Call. With me today from management are Vimal Mehta, Chief Executive Officer; and Richard Steinhart, Chief Financial Officer. Vince O'Neill, our Chief Medica
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting [YY
- BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingGlobeNewswire
- BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialGlobeNewswire
BTAI
Earnings
- 3/12/24 - Beat
BTAI
Sec Filings
- 4/22/24 - Form 8-K
- 4/19/24 - Form PRE
- 4/10/24 - Form 8-K
- BTAI's page on the SEC website